Nyla A. Heerema

Active 1985–2025

148
Papers
34,115
Citations
98
h-index
146
i10-index

Citations

Citations per year for Nyla A. Heerema1986: 3 citations1987: 4 citations1988: 2 citations1989: 3 citations1990: 12 citations1991: 12 citations1992: 3 citations1993: 9 citations1994: 9 citations1995: 3 citations1996: 1 citations1997: 20 citations1998: 33 citations1999: 32 citations2000: 67 citations2001: 32 citations2002: 60 citations2003: 59 citations2004: 62 citations2005: 75 citations2006: 105 citations2007: 145 citations2008: 189 citations2009: 218 citations2010: 281 citations2011: 225 citations2012: 292 citations2013: 261 citations2014: 319 citations2015: 449 citations2016: 322 citations2017: 344 citations2018: 344 citations2019: 1,125 citations2020: 1,140 citations2021: 1,170 citations2022: 741 citations2023: 554 citations2024: 856 citations2025: 336 citations2026: 8 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,544 citing papers, 30.1% of this breakdownGermany: 851 citing papers, 7.2% of this breakdownUnited Kingdom: 793 citing papers, 6.7% of this breakdownItaly: 652 citing papers, 5.5% of this breakdownChina: 645 citing papers, 5.5% of this breakdownFrance: 485 citing papers, 4.1% of this breakdownNetherlands: 406 citing papers, 3.4% of this breakdownCanada: 405 citing papers, 3.4% of this breakdownAustralia: 364 citing papers, 3.1% of this breakdownSpain: 330 citing papers, 2.8% of this breakdownSwitzerland: 241 citing papers, 2.1% of this breakdownJapan: 221 citing papers, 1.9% of this breakdown
0%30.1%Other 24.2%

Fields

  • Medicine74.2%
  • Biochemistry, Genetics and Molecular Biology20.2%
  • Immunology and Microbiology3%
  • Agricultural and Biological Sciences0.7%
  • Chemistry0.5%
  • Computer Science0.3%
  • Other1.1%

Topics

  • Acute Lymphoblastic Leukemia research10.7%
  • Chronic Lymphocytic Leukemia Research8.5%
  • Acute Myeloid Leukemia Research8.4%
  • Lymphoma Diagnosis and Treatment6.4%
  • Chronic Myeloid Leukemia Treatments5.2%
  • Childhood Cancer Survivors' Quality of Life4.1%
  • Other56.7%

Coauthors

All papers

Open in search
  1. The genomic landscape of pediatric acute lymphoblastic leukemia

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Scott G. Foy, Dale J. Hedges, Scott Newman, Xin Zhou, Jian Wang, Colleen Reilly, Edgar Sioson, Stephen V. Rice, Victor Pastor Loyola, Gang Wu, Evadnie Rampersaud, Shalini C. Reshmi, Julie M. Gastier-Foster, Jaime M. Guidry Auvil, Patee Gesuwan, Malcolm A. Smith, Naomi Winick, Andrew J. Carroll, Nyla A. Heerema, Richard C. Harvey, Cheryl L. Willman, Eric Larsen, Elizabeth A. Raetz, Michael J. Borowitz, Brent L. Wood, William L. Carroll, Patrick A. Zweidler‐McKay, Karen R. Rabin, Leonard A. Mattano, Kelly W. Maloney, Stuart S. Winter, Michael J. Burke, Wanda L. Salzer, Kimberly P. Dunsmore, Anne Angiolillo, Kristine R. Crews, James R. Downing, Sima Jeha, Ching‐Hon Pui, William E. Evans, Jun J. Yang, Mary V. Relling, Daniela S. Gerhard, Mignon L. Loh, Stephen P. Hunger, Jinghui Zhang, Charles G. Mullighan - Nature Genetics 2022 cited by 397

  2. The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Kimberly P. Dunsmore, Stuart S. Winter, Brent L. Wood, Brian P. Sorrentino, James R. Downing, Mignon L. Loh, Stephen P. Hunger, Jinghui Zhang, Charles G. Mullighan - Nature Genetics 2017 cited by 934

  3. Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , John C. Byrd - New England Journal of Medicine 2018 cited by 952

  4. Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia

    Authors: , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2013 cited by 2,249

  5. Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Panduka Nagahawatte, Gang Wu, Xiang Chen, Donald Yergeau, Bhavin Vadodaria, Heather L. Mulder, Naomi Winick, Eric Larsen, William L. Carroll, Nyla A. Heerema, Andrew J. Carroll, Guy H. Grayson, Sarah K. Tasian, Andrew S. Moore, Frank Keller, Melissa Frei‐Jones, James A. Whitlock, Elizabeth A. Raetz, Deborah L. White, Timothy P. Hughes, Jaime M. Guidry Auvil, Malcolm A. Smith, Guido Marcucci, Clara D. Bloomfield, Krzysztof Mrózek, Jessica Kohlschmidt, Wendy Stock, Steven M. Kornblau, Marina Konopleva, Elisabeth Paietta, Ching‐Hon Pui, Sima Jeha, Mary V. Relling, William E. Evans, Daniela S. Gerhard, Julie M. Gastier-Foster, Elaine R. Mardis, Richard K. Wilson, Mignon L. Loh, James R. Downing, Stephen P. Hunger, Cheryl L. Willman, Jinghui Zhang, Charles G. Mullighan - New England Journal of Medicine 2014 cited by 1,376

  6. BTKC481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Amy J. Johnson, John C. Byrd - Journal of Clinical Oncology 2017 cited by 471

  7. The genetic basis and cell of origin of mixed phenotype acute leukaemia

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Brent L. Wood, Nyla A. Heerema, Andrew Carrol, Yung‐Li Yang, Malcolm A. Smith, Tanja M. Davidsen, Leandro C. Hermida, Patee Gesuwan, Marco A. Marra, Yussanne Ma, Andrew J. Mungall, Richard A. Moore, Steven J.M. Jones, Marcus B. Valentine, Laura J. Janke, Jeffrey E. Rubnitz, Ching‐Hon Pui, Liang Ding, Yu Liu, Jinghui Zhang, Kim E. Nichols, James R. Downing, Xueyuan Cao, Lei Shi, Stanley Pounds, Scott Newman, Deqing Pei, Jaime M. Guidry Auvil, Daniela S. Gerhard, Stephen P. Hunger, Hiroto Inaba, Charles G. Mullighan - Nature 2018 cited by 374

  8. Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia

    Authors: , , , , , , , , , , , , , , , , , , , , - JAMA Oncology 2015 cited by 576

  9. Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Christine Vietz, Eric A. Severson, Molly Miller, Leonard Rosenberg, Sonja Marcus, Ashley O. Yocum, Timothy F. Chen, Mona Stefanos, Brian Druker, John C. Byrd - Nature Medicine 2020 cited by 192

  10. Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study

    Authors: , , , , , , , , , , , , , - Clinical Cancer Research 2020 cited by 183

  11. Outcome in Children With Standard-Risk B-Cell Acute Lymphoblastic Leukemia: Results of Children’s Oncology Group Trial AALL0331

    Authors: , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2019 cited by 198

  12. The genomic landscape of hypodiploid acute lymphoblastic leukemia

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Charles Lu, Robert S. Fulton, Lucinda Fulton, Yashodhan Tabib, David J. Dooling, Kerri Ochoa, Mark D. Minden, Ian D. Lewis, L.B. To, Paula Marlton, Andrew W. Roberts, Gordana Raca, Wendy Stock, Geoffrey Neale, Hans G. Drexler, Ross A. Dickins, David W. Ellison, Sheila Shurtleff, Ching‐Hon Pui, Raul C. Ribeiro, Meenakshi Devidas, Andrew J. Carroll, Nyla A. Heerema, Brent L. Wood, Michael J. Borowitz, Julie M. Gastier‐Foster, Susana C. Raimondi, Elaine R. Mardis, Richard K. Wilson, James R. Downing, Stephen P. Hunger, Mignon L. Loh, Charles G. Mullighan - Nature Genetics 2013 cited by 728

  13. Children’s Oncology Group AALL0434: A Phase III Randomized Clinical Trial Testing Nelarabine in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia

    Authors: , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2020 cited by 255

  14. Dexamethasone and High-Dose Methotrexate Improve Outcome for Children and Young Adults With High-Risk B-Acute Lymphoblastic Leukemia: A Report From Children’s Oncology Group Study AALL0232

    Authors: , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2016 cited by 380

  15. Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , David Webb, Zuzana Zemanová, C. Michel Zwaan, Marry M. van den Heuvel‐Eibrink - Blood 2009 cited by 447

  16. Phase II Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naïve and Relapsed or Refractory Chronic Lymphocytic Leukemia

    Authors: , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2020 cited by 104

  17. Improved Survival for Children and Young Adults With T-Lineage Acute Lymphoblastic Leukemia: Results From the Children’s Oncology Group AALL0434 Methotrexate Randomization

    Authors: , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2018 cited by 237

  18. Pre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in Eμ-miR155 transgenic mice

    Authors: , , , , , , - National Academy of Sciences, Proceedings of the National Academy of Sciences 2006 cited by 943

  19. Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib

    Authors: , , , , , , , , , , , , , , , - Blood 2015 cited by 656

  20. Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children's Oncology Group Study AALL0031

    Authors: , , , , , , , , , , , , , , , , , , , - Leukemia 2014 cited by 449

  21. Constitutional and somatic rearrangement of chromosome 21 in acute lymphoblastic leukaemia

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Peter Van Loo, Michael R. Stratton, Peter J. Campbell, Christine J. Harrison - Nature 2014 cited by 286

  22. Dasatinib Plus Intensive Chemotherapy in Children, Adolescents, and Young Adults With Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia: Results of Children’s Oncology Group Trial AALL0622

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2018 cited by 250

  23. Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib

    Authors: , , , , , , , , , , , , , , , , , , , , , , - Blood Advances 2017 cited by 162

  24. Excellent Outcomes With Reduced Frequency of Vincristine and Dexamethasone Pulses in Standard-Risk B-Lymphoblastic Leukemia: Results From Children's Oncology Group AALL0932

    Authors: , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2021 cited by 101